Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25680984 | 0.89 | TP53 (0.80) | TP53NPSR1PKMMAPTALDH1A1 | |
| SCHEMBL25939512 | 0.89 | TP53 (0.80) | TP53NPSR1PKMMAPTALDH1A1 | |
| SCHEMBL12418317 | 0.85 | TP53 (0.73) | TP53NPSR1PKMMAPTALDH1A1 | |
| SCHEMBL15543572 | 0.85 | TP53 (0.73) | TP53NPSR1PKMMAPTALDH1A1 | |
| SCHEMBL19750781 | 0.85 | TP53 (0.73) | TP53NPSR1MAPTALDH1A1HTT | |
| SCHEMBL3013834 | 0.85 | TP53 (0.73) | TP53NPSR1PKMMAPTALDH1A1 | |
| SCHEMBL561797 | 0.80 | TP53 (0.67) | TP53NPSR1PKMMAPTALDH1A1 | |
| SCHEMBL14419946 | 0.80 | TP53 (0.66) | TP53NPSR1MAPTALDH1A1HTT | |
| SCHEMBL31167009 | 0.78 | TP53 (0.64) | TP53NPSR1PKMMAPTALDH1A1 | |
| SCHEMBL12437005 | 0.78 | TP53 (0.63) | TP53NPSR1MAPTALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110891951-B | Compounds of formula (I) | 谢菲尔德大学 | 2024-08-20 | — | — | CN | disclosed |
| EP-3628045-B1 | COMPOUNDS | UNIV SHEFFIELD (GB) | 2024-07-03 | — | — | EP | disclosed |
| EP-3628045-B1 | COMPOUNDS | UNIV SHEFFIELD (GB) | 2024-07-03 | — | — | EP | disclosed |
| US-11400081-B2 | Compounds | THE UNIVERSITY OF SHEFFIELD (GB) | 2022-08-02 | — | — | US | disclosed |
| US-20210113534-A1 | COMPOUNDS | THE UNIVERSITY OF SHEFFIELD (GB) | 2021-04-22 | — | — | US | disclosed |
| US-20210113534-A1 | COMPOUNDS | THE UNIVERSITY OF SHEFFIELD (GB) | 2021-04-22 | — | — | US | disclosed |
| EP-3628045-A1 | COMPOUNDS | The University Of Sheffield (GB) | 2020-04-01 | — | — | EP | disclosed |
| CN-110891951-A | Compound (I) | 谢菲尔德大学 | 2020-03-17 | — | — | CN | disclosed |
| WO-2018211275-A1 | COMPOUNDS | THE UNIVERSITY OF SHEFFIELD (GB) | 2018-11-22 | — | — | WO | disclosed |
| US-6294573-B1 | FOR THERAPY RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPENIAS SUCH AS OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, AND TUMOR GROWTH AND METASTASIS OR INVASION | ABBOTT LABORATORIES | 2001-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210113534-A1 | COMPOUNDS | MRGPRX2, MC2R, ADM2 | TP53 1048/4885NPSR1 97/4885PKM 3603/4885 |
| US-11400081-B2 | Compounds | MRGPRX2, MC2R, ADM2 | TP53 1048/4885NPSR1 97/4885PKM 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.